Brief Review of Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel— Mevorach 2021
This is a brief audio review. In the article Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel published, 2021 by Mevorach and Colleagues, The outcomes and key points are as noted: BNT162B2 vaccine resulted in an increased incidence of mild myocarditis, more likely after the second vaccination dose in young male patients; Rate ratio 2.23 or 2.35 (95% Confidence Interval 1.10 to 5.02), accounting for 30 day myocarditis event in vaccinated individuals versus unvaccinated. Rate ratio 8.96 (95% Confidence Interval 4.50 to 17.83), accounting for male vaccine recipients between 16 to 19 years old In a Retrospective, cohort, descriptive, [observational] study with 446,163,792 person days of follow up patients who were all individuals included in the country's public health surveillance system; broken down by vaccinated individuals and unvaccinated individuals in the country (Israel).
Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, Olsha-Castell S, Arad D, Hasin T, Levi N, Asleh R, Amir O, Meir K, Cohen D, Dichtiar R, Novick D, Hershkovitz Y, Dagan R, Leitersdorf I, Ben-Ami R, Miskin I, Saliba W, Muhsen K, Levi Y, Green MS, Keinan-Boker L, Alroy-Preis S. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med. 2021 Dec 2;385(23):2140-2149. doi: 10.1056/NEJMoa2109730. Epub 2021 Oct 6. PMID: 34614328; PMCID: PMC8531987.
